Consistent with these recommendations, our study showed that in insulin-treated patients with T2D, GLP-1 RA use significantly reduced the risk of hospitalization for coronary artery disease compared with DPP-4 inhibitor and sulfonylurea use. Here, DPP4 is linked to type 2 diabetes mellitus.